Biotech
-
Q&A // First 90 Days
Why Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’
The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.
By Alexandra Pecci • Sept. 26, 2023 -
Profile
Three years after an FDA rejection, DBV sees a path for its peanut patch
Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.
By Karissa Waddick • Sept. 22, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineCell and gene therapies
How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.
By PharmaVoice staff -
What happened to ivermectin?
The saga of the anti-parasitic drug continues.
By Alexandra Pecci • Sept. 20, 2023 -
The 2023 PharmaVoice 100
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
By Julia Himmel • Sept. 19, 2023 -
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
By Michael Gibney • Sept. 15, 2023 -
Q&A
In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
By Michael Gibney • Sept. 14, 2023 -
Catching up with 2022 PharmaVoice 100 honorees
Tapping into our growing community for expertise and inspiration.
By Meagan Parrish • Sept. 13, 2023 -
A tale of two biotechs — 2seventy, Regeneron announce C-suite shakeups
The biotech’s chief financial officer Robert Landry is retiring in February.
By Karissa Waddick • Sept. 12, 2023 -
A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say
A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.
By Alexandra Pecci • Sept. 12, 2023 -
Ex-Sanofi executive Sibold joins Madrigal as new CEO
Bill Sibold has led Sanofi's specialty care business unit for the past six years. He replaces Paul Friedman as head of the NASH drug developer.
By Ned Pagliarulo • Sept. 11, 2023 -
Biotech Spotlight
Immuneering takes aim at cancer’s ‘superhighway’
After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.
By Kelly Bilodeau • Sept. 11, 2023 -
Profile
‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride
Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.
By Michael Gibney • Sept. 7, 2023 -
Profile
Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery
Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.
By Alexandra Pecci • Sept. 6, 2023 -
A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?
Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.
By Meagan Parrish • Sept. 1, 2023 -
Lawmakers are already gunning for more dramatic drug pricing reforms
Medicare just announced its first-ever drug price negotiations and legislators are quickly pushing to broaden the program.
By Karissa Waddick • Aug. 31, 2023 -
Medicare named the first 10 drugs up for negotiation. Now what?
The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.
By Karissa Waddick • Aug. 30, 2023 -
Q&A // Biotech Spotlight
‘We need to do better:’ A biotech CEO on standing apart from the crowd
The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.
By Michael Gibney • Aug. 29, 2023 -
Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’
FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages.
By Karissa Waddick • Aug. 25, 2023 -
‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax
New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.
By Michael Gibney • Aug. 24, 2023 -
Henrietta Lacks’ immortal cells put biopharma profits under a microscope
The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.
By Michael Gibney • Aug. 23, 2023 -
Biotech Spotlight
Brii Biosciences aims to come up big where Sage and Biogen fell short
The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.
By Kelly Bilodeau • Aug. 21, 2023 -
Behind Flagship Pioneering’s triumphs and tribulations
From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.
By Karissa Waddick • Aug. 18, 2023 -
Pharma’s rare disease rush
Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?
By Meagan Parrish , Karissa Waddick • Aug. 14, 2023 -
Q&A // Biotech Spotlight
Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine
The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.
By Kelly Bilodeau • Aug. 14, 2023 -
Q&A
5 minutes with — Lundbeck CEO Dr. Deborah Dunsire
The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.
By Meagan Parrish • Aug. 11, 2023